8-K: Amwell Announces Fourth Quarter and Full Year 2024 Results, Focuses on Profitability

Amwell reports Q4 and full-year 2024 results, highlighting revenue, adjusted EBITDA improvements, and a path to positive cash flow in 2026.

Summary

• Amwell announced its Q4 and full-year 2024 financial results.
• Total revenue for Q4 2024 was $71.0 million, with subscription revenue at $36.9 million and Amwell Medical Group (AMG) visit revenue at $29.2 million.
• The gross margin for Q4 was 48%.
• Net loss for Q4 was ($44.6) million, compared to ($44.0) million in Q3 2024.
• Adjusted EBITDA for Q4 was ($22.8) million, an improvement from ($31.0) million in Q3 2024.
• Total visits in Q4 were 1.4 million.
• For the full year 2024, total revenue was $254.4 million, including $115.5 million in subscription revenue and $116.5 million in AMG visit revenue.
• The full-year gross margin was 39%.
• The net loss for the full year was ($212.6) million, compared to ($679.2) million in 2023, which included non-cash goodwill impairment charges of $436.5 million.
• Adjusted EBITDA for the full year was ($134.4) million, an improvement from ($165.4) million in 2023.
• Total visits for the full year were 5.9 million.
• Cash and short-term securities at year-end were approximately $228.3 million.
• The company aims to achieve positive cash flow in 2026.
• 2025 revenue is projected to be in the range of $250 to $260 million.
• AMG visits for 2025 are expected to be between 1.3 and 1.35 million.
• Adjusted EBITDA for 2025 is projected to be between ($55) million and ($45) million.
• Q1 2025 revenue is expected to be in the range of $59 to $61 million.
• Q1 2025 adjusted EBITDA is projected to be between ($18) million and ($20) million.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still reporting losses, there are improvements in adjusted EBITDA and a clear plan to achieve positive cash flow in 2026. The successful launch of the solution across the U.S. Military Health System is also a positive sign.

Positives

• Adjusted EBITDA improved both in Q4 and for the full year 2024 compared to the previous periods.
• The company is focusing on quality of revenue and margin initiatives.
• Amwell is successfully launching its full solution across the U.S. Military Health System.
• Amwell has a robust cash position with approximately $228.3 million in cash and short-term securities as of year-end.
• The company is undertaking meaningful quality of revenue and margin initiatives that are resulting in steady, better-than-expected quarterly improvements in adjusted EBITDA.
• Amwell is successfully refining its business to deliver on the expectations of stakeholders, advancing us to generate positive cash flow during 2026, with a robust cash position.

Negatives

• The company reported a net loss of ($44.6) million for Q4 2024.
• The company reported a net loss of ($212.6) million for the full year 2024.
• The company is still operating at a loss, with negative adjusted EBITDA.
• The company provided 2025 financial guidance calls for: Revenue in the range of $250 to $260 million (this reflects the previously announced divestiture of Amwell Psychiatric Care).

Risks

• The company's forward-looking statements are subject to risks and uncertainties.
• These risks include the ability to transition clients to Converge, renew and upsell the client base, and maintain the DHA relationship.
• Other risks include weak growth in the telehealth market, rapid technological changes, increased competition, and changes in healthcare laws and regulations.
• The company also faces risks related to privacy regulations and cybersecurity breaches.

Future Outlook

Amwell expects revenue in the range of $250 to $260 million and adjusted EBITDA between ($55) million and ($45) million for 2025, with a goal to achieve positive cash flow in 2026.

Management Comments

• Ido Schoenberg, MD, chairman and CEO of Amwell, stated that the company advanced its business in ways that put it much closer to unlocking the value of Amwell and advancing its mission to modernize healthcare with its unified platform.
• He also noted the successful launch of their full solution across the U.S. Military Health System with partners at Leidos.
• Management stated that they are successfully refining their business to deliver on the expectations of stakeholders, advancing them to generate positive cash flow during 2026, with a robust cash position.

Industry Context

Amwell operates in the telehealth industry, which is experiencing growth and increased competition. The company's focus on a comprehensive SaaS-based platform and partnerships with major health systems and payers positions it to capitalize on the increasing demand for digital health solutions.

Comparison to Industry Standards

• Teladoc Health, a major competitor in the telehealth space, reported revenue of $2.4 billion in 2023.
• Amwell's revenue of $254.4 million for 2024 is significantly lower, indicating a smaller market share.
• However, Amwell's focus on a platform-based approach and partnerships with large health systems could differentiate it from competitors focused primarily on direct-to-consumer telehealth services.
• Companies like Cerner and Epic also offer telehealth solutions as part of their broader healthcare IT platforms, posing competition to Amwell.
• The adjusted EBITDA margins of telehealth companies vary widely, with some achieving profitability while others are still investing heavily in growth.

Stakeholder Impact

• Shareholders may be encouraged by the improvements in adjusted EBITDA and the plan to achieve positive cash flow, but remain concerned about the ongoing losses.
• Employees may be affected by the strategic transformation initiatives, which include severance and cost structure changes.
• Customers and partners may benefit from the company's focus on a comprehensive platform and its partnerships with major health systems and payers.
• The company's ability to comply with privacy regulations and prevent cybersecurity breaches is critical to maintaining trust with stakeholders.

Next Steps

• Amwell will host a conference call to discuss its financial results on February 12, 2025.
• The company will continue to focus on transitioning clients to Converge, renewing and upselling its client base, and maintaining its relationship with the DHA.
• Amwell will continue to execute its strategic transformation initiatives to improve profitability and achieve positive cash flow in 2026.

Key Dates